Filing of Form 20-F with SEC

RNS Number : 6062Q

AstraZeneca PLC

22 February 2023

 

22 February 2023 07:10 GMT

Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission

AstraZeneca PLC (the Company) announced today that, on 21 February  2023, it filed its 2022 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC). The document is available for viewing on the SEC website at  www.sec.gov and also on the Company's website at  www.astrazeneca.com . The Company will send any holder of the Company's securities, upon request, a hard copy of the Company's complete audited financial statements free of charge. Requests may be made by writing to the Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca .

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

END

 

 

MSCSEIFDFEDSEDE